home All News open_in_new Full Article

Ipilimumab N01 Plus Sintilimab Earns NMPA Approval in China for Resectable MSI

Ipilimumab N01 Plus Sintilimab Earns NMPA Approval in China for Resectable MSI-H/dMMR Colon Cancer  OncLive


today 2 w. ago attach_file Politics

attach_file Politics
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 938415682
Add Watch Country

arrow_drop_down